Literature DB >> 22253322

Complement C3 is a novel plasma clot component with anti-fibrinolytic properties.

Joanna-Marie Howes1, Victoria R Richardson, Kerrie A Smith, Verena Schroeder, Riyaz Somani, Anna Shore, Katharina Hess, Ramzi Ajjan, Richard J Pease, Jeffrey N Keen, Kristina F Standeven, Angela M Carter.   

Abstract

BACKGROUND AND
METHOD: Increased plasma clot density and prolonged lysis times are associated with cardiovascular disease. In this study, we employed a functional proteomics approach to identify novel clot components which may influence clot phenotypes.
RESULTS: Analysis of perfused, solubilised plasma clots identified inflammatory proteins, including complement C3, as novel clot components. Analysis of paired plasma and serum samples confirmed concentration-dependent incorporation of C3 into clots. Surface plasmon resonance indicated high-affinity binding interactions between C3 and fibrinogen and fibrin. Turbidimetric clotting and lysis assays indicated C3 impaired fibrinolysis in a concentration-dependent manner, both in vitro and ex vivo.
CONCLUSION: These data indicate functional interactions between complement C3 and fibrin leading to prolonged fibrinolysis. These interactions are physiologically relevant in the context of protection following injury and suggest a mechanistic link between increased plasma C3 concentration and acute cardiovascular thrombotic events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22253322     DOI: 10.1177/1479164111432788

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  27 in total

1.  Demographic and Technical Risk Factors of 30-Day Stroke, Myocardial Infarction, and/or Death in Standard- and High-Risk Patients Who Underwent Carotid Angioplasty and Stenting.

Authors:  Afshin Borhani Haghighi; Samaneh Yousefi; Ehsan Bahramali; Safoora Kokabi; Seyed Taghi Heydari; Abdolhamid Shariat; Alireza Nikseresht; Nahid Ashjazadeh; Sadegh Izadi; Peyman Petramfar; Maryam Poursadegh; Abbas Rahimi Jaberi; Sajjad Emami; Hamid Agheli; Reza Nemati; Ehsan Yaghoubi; Mohammad Hosein Abdi; Majid Panahandeh; Moslem Heydari; Anahid Safari; Marziyeh Basir; Salvador Cruz-Flores; Randal Edgell
Journal:  Interv Neurol       Date:  2015-07

2.  Menopause, complement, and hemostatic markers in women at midlife: the Study of Women's Health Across the Nation.

Authors:  Samar R El Khoudary; Kelly J Shields; Hsiang-Yu Chen; Karen A Matthews
Journal:  Atherosclerosis       Date:  2013-09-05       Impact factor: 5.162

3.  Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Authors:  Reinhard J Sauter; Manuela Sauter; Edimara S Reis; Frederic N Emschermann; Henry Nording; Sonja Ebenhöch; Peter Kraft; Patrick Münzer; Maximilian Mauler; Johannes Rheinlaender; Johannes Madlung; Frank Edlich; Tilman E Schäffer; Sven G Meuth; Daniel Duerschmied; Tobias Geisler; Oliver Borst; Meinrad Gawaz; Christoph Kleinschnitz; John D Lambris; Harald F Langer
Journal:  Circulation       Date:  2018-10-16       Impact factor: 29.690

Review 4.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

5.  Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor.

Authors:  Caroline S Gravastrand; Bjørg Steinkjer; Bente Halvorsen; Anne Landsem; Mona Skjelland; Eva Astrid Jacobsen; Trent M Woodruff; John D Lambris; Tom E Mollnes; Ole-Lars Brekke; Terje Espevik; Anne Mari A Rokstad
Journal:  J Immunol       Date:  2019-07-03       Impact factor: 5.422

Review 6.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

Authors:  R J King; P J Grant
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

7.  Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.

Authors:  Katherine A Shuster; Shirley K Wrobleski; Angela E Hawley; Benedict R Lucchesi; Dorothy R Sorenson; Ingrid L Bergin; Robert E Sigler; Kenneth E Guire; Megan H Nowland; Thomas W Wakefield; Daniel D Myers
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

8.  Identification of fibrin clot-bound plasma proteins.

Authors:  Simone Talens; Frank W G Leebeek; Jeroen A A Demmers; Dingeman C Rijken
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.

Authors:  Katharina Hess; Ramzi Ajjan; Fladia Phoenix; József Dobó; Péter Gál; Verena Schroeder
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

10.  Alternative Complement Pathway Activation Provokes a Hypercoagulable State with Diminished Fibrinolysis.

Authors:  Jason M Samuels; Julia R Coleman; Ernest E Moore; Matt Bartley; Navin Vigneshwar; Mitchell Cohen; Christopher C Silliman; Angela Sauaia; Anirban Banerjee
Journal:  Shock       Date:  2020-05       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.